Label-free Electrochemical Immunosensor for Sensitive Detection of Rheumatoid Arthritis Biomarker Anti-CCP-ab

The accurate and sensitive analysis of rheumatoid arthritis(RA) trace biomarkers is essential for early warning and diagnosis of RA, while anti-cyclic citrullinated peptide antibody (anti-CCP-ab) is a specific one. In this study, a simple label-free electrochemical immunosensor for the detection of anti-CCP-ab was constructed with nitrogen-doped graphene (N−G) and gold nanoparticles (AuNPs). The proposed non-enzyme immunosensor had exhibited high specificity, selectivity, and stability in the linear calibration curve range from 0.125∼2000 pg mL-1 and has been successfully used in the detection of anti-CCP-ab in human serum, providing a new idea for the early diagnosis of RA.     

雷公藤治疗老年性类风湿性关节炎临床实验研究

试验用雷公藤治疗老年性类风湿性关节炎。治疗效果表明,55例近期总有效率达98．18％,且尚可作为皮质激素的良好替代药物;雷公藤副作用轻微,与同期中青年组比较,无显著性差异（P＞0．05）,表明短期使用雷公藤治疗老年性类风湿关节炎是安全有效的。     

基于气相色谱-飞行时间质谱技术的佐剂性关节炎大鼠尿液代谢组学的研究

采用弗氏完全佐剂(FCA)诱导佐剂性关节炎(AA)大鼠模型,观察大鼠足趾肿胀度和踝关节组织的病理学形态变化。应用气相色谱-飞行时间质谱(GC-TOF MS)技术检测AA大鼠尿液代谢物谱,并对数据进行主成分分析(PCA)、偏最小二乘法-判别分析(PLS-DA)及正交偏最小二乘法-判别分析(OPLS-DA),探讨可能的发病机制。通过变量重要性投影值(VIP>1)和P值(<0.05),筛选出尿液中的差异代谢物。在模型组大鼠的尿液中共发现异柠檬酸、α-酮戊二酸、柠康酸、肌酸、3-羟基丁酸等20种差异代谢物。推断AA代谢组学的发病机制可能与能量代谢、氨基酸代谢、脂肪酸代谢途径有关。     

厚藤提取物对胶原诱导关节炎模型大鼠的治疗作用研究

为探究厚藤(Ipomoea pes-caprae)提取物对胶原诱导关节炎(Collagen-induced Arthritis,CIA)模型大鼠的治疗作用,本研究采用牛Ⅱ型胶原诱导建立CIA大鼠模型,观察厚藤提取物高、中、低剂量组(2.2712,1.1356,0.5678 g/kg)对CIA大鼠踝关节肿胀、足跖肿胀、关...     

The Protective Effects of Neoastilbin on Monosodium Urate Stimulated THP-1-Derived Macrophages and Gouty Arthritis in Mice through NF-κB and NLRP3 Inflammasome Pathways

Gouty arthritis (GA) is a frequent inflammatory disease characterized by pain, swelling, and stiffness of joints. Neoastilbin is a flavonoid isolated from the rhizome of Smilax glabra, which possesses various anti-inflammatory effects. However, the mechanism of neoastilbin in treating GA has not yet been clarified. Thus, this study was to investigate the protective effects of neoastilbin in both monosodium urate (MSU) stimulated THP-1-derived macrophages and the animal model of GA by injecting MSU into the ankle joints of mice. The levels of key inflammatory cytokines in MSU stimulated THP-1-derived macrophages were detected by enzyme-linked immunosorbent assay (ELISA) kits. Protein expressions of nuclear factor kappa B (NF-κB) and NOD-like receptor protein 3 (NLRP3) inflammasome pathways were further detected by Western blotting. In addition, swelling degree of ankle joints, the levels of inflammatory factors, infiltration of inflammatory cells and the expressions of related proteins were determined. Swelling degree and histopathological injury in ankle joints of MSU-injected mice were significantly decreased after being treated with neoastilbin. Moreover, neoastilbin significantly diminished the secretion of interleukin-1β (IL-1β), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α), suppressing the activation of NF-κB and NLRP3 inflammasome pathways in both MSU stimulated THP-1-derived macrophages and the mouse model of GA. In summary, neoastilbin could alleviate GA by inhibiting the NF-κB and NLRP3 inflammasome pathways, which provided some evidence for neoastilbin as a promising therapeutic agent for GA treatment.     

Self-Nanoemulsifying Drug Delivery System (SNEDDS) of Apremilast: In Vitro Evaluation and Pharmacokinetics Studies

Psoriatic arthritis is an autoimmune disease of the joints that can lead to persistent inflammation, irreversible joint damage and disability. The current treatments are of limited efficacy and inconvenient. Apremilast (APR) immediate release tablets Otezla^® have 20–33% bioavailability compared to the APR absolute bioavailability of 73%. As a result, self-nanoemulsifying drug delivery systems (SNEDDS) of APR were formulated to enhance APR’s solubility, dissolution, and oral bioavailability. The drug assay was carried out using a developed and validated HPLC method. Various thermodynamic tests were carried out on APR-SNEDDS. Stable SNEDDS were characterized then subjected to in vitro drug release studies via dialysis membrane. The optimum formulation was F9, which showed the maximum in vitro drug release (94.9%) over 24 h, and this was further investigated in in vivo studies. F9 was composed of 15% oil, 60% S_mix, and 25% water and had the lowest droplet size (17.505 ± 0.247 nm), low PDI (0.147 ± 0.014), low ZP (−13.35 mV), highest %T (99.15 ± 0.131) and optimum increases in the relative bioavailability (703.66%) compared to APR suspension (100%) over 24 h. These findings showed that APR-SNEDDS is a possible alternative delivery system for APR. Further studies are warranted to evaluate the major factors that influence the encapsulation efficiency and stability of APR-containing SNEDDS.     

猪关节炎型链球菌的分离与鉴定

对唐山某养猪场流行的一种以腿部关节肿大为特征的慢性疾病,进行了细菌的分离纯化、形态和培养特性观察、生化鉴定、药敏试验和动物感染试验,发现此病是由α溶血型链球菌引起的猪链球菌病,此细菌具有致病性,但是细菌的种群未测定出。建议猪场采取积极措施进行药物治疗和疫苗免疫。     

Investigating Antiarthritic Potential of Nanostructured Clove Oil (Syzygium aromaticum) in FCA-Induced Arthritic Rats: Pharmaceutical Action and Delivery Strategies

The combined application of clove oil in a lipid nanocarrier opens a promising avenue for bone and joints therapy. In this study, we successfully developed a tunable controlled-release lipid platform for the efficient delivery of clove oil (CO) for the treatment of rheumatoid arthritis (RA). The ultra-small nanostructured lipid carriers co-loaded with CO (CONCs) were developed through an aqueous titration method followed by microfluidization. The CONCs appeared to be spherical (particle size of 120 nm), stable (zeta potential of −27 mV), and entrapped efficiently (84.5%). In toluene:acetone:glacial acetic acid (90:9:1 percent v/v/v) solvent systems, high-performance thin layer chromatography (HPTLC) analysis revealed the primary components in CO as eugenol (R_F = 0.58). The CONCs greatly increased the therapeutic impact of CO in both in vitro and in vivo biological tests, which was further supported by excellent antiarthritic action. The CONC had an antiarthritic activity that was slightly higher than neat CO and slightly lower than standard, according to our data. The improved formulation inhibited serum lysosomal enzymes and proinflammatory cytokines while also improving hind leg function. This study provides a proof of concept to treat RA with a new strategy utilizing essential oils via nanodelivery.     

An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022

Since the early 1980s, phosphodiesterase 4 (PDE4) has been an attractive target for the treatment of inflammation-based diseases. Several scientific advancements, by both academia and pharmaceutical companies, have enabled the identification of many synthetic ligands for this target, along with the acquisition of precise information on biological requirements and linked therapeutic opportunities. The transition from pre-clinical to clinical phase was not easy for the majority of these compounds, mainly due to their significant side effects, and it took almost thirty years for a PDE4 inhibitor to become a drug i.e., Roflumilast, used in the clinics for the treatment of chronic obstructive pulmonary disease. Since then, three additional compounds have reached the market a few years later: Crisaborole for atopic dermatitis, Apremilast for psoriatic arthritis and Ibudilast for Krabbe disease. The aim of this review is to provide an overview of the compounds that have reached clinical trials in the last ten years, with a focus on those most recently developed for respiratory, skin and neurological disorders.     

痛利舒颗粒治疗急性痛风性关节炎的实验研究

通过对痛利舒颗粒的相关药理学研究,评价其对急性痛风性关节炎的治疗作用。建立尿酸钠致急性痛风性关节炎大鼠模型,给予痛利舒颗粒3.24、6.48、12.96 g/kg,考察对踝关节肿胀程度的改善情况;采用热板法测定小鼠痛阈值,给予痛利舒颗粒4.68、9.36、18.72 g/kg,评价其镇痛作用效果;建立巴豆油致小鼠耳廓肿胀模型,给予痛利舒颗粒4.68、9.36、18.72 g/kg,观察其抗炎作用的效果。结果显示,痛利舒颗粒可以改善大鼠踝关节肿胀程度和降低炎症因子TNF α、IL 6含量,提高热板法所测的小鼠的痛阈值,具有一定的镇痛作用,亦对巴豆油所致小鼠耳廓肿胀有一定的抗炎作用。